Gene:
CYLD
cylindromatosis (turban tumor syndrome)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  ubiquitin specific peptidase like 2
Alternate Symbols:  KIAA0849; USPL2
PharmGKB Accession Id: PA27084

Details

Cytogenetic Location: chr16 : q12.1 - q12.1
GP mRNA Boundary: chr16 : 50775961 - 50835846
GP Gene Boundary: chr16 : 50765961 - 50838846
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. Canonical NF-kappaB pathway - (Pathway Interaction Database NCI-Nature Curated)
  2. TNF receptor signaling pathway - (Pathway Interaction Database NCI-Nature Curated)

Publications related to CYLD: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gene ontology analysis of GWA study data sets provides insights into the biology of bipolar disorder. American journal of human genetics. 2009. Holmans Peter, et al. PubMed

LinkOuts

UniProtKB:
CYLD_HUMAN (Q9NQC7)
Ensembl:
ENSG00000083799
GenAtlas:
CYLD
GeneCard:
CYLD
MutDB:
CYLD
ALFRED:
LO073512S
HuGE:
CYLD
Comparative Toxicogenomics Database:
1540
ModBase:
Q9NQC7
HumanCyc Gene:
HS01450
HGNC:
2584

Common Searches